The Lady Vanishes

[biopearl123]

So does IR it appears.

No response as yet:

Dear Dawn, I write to you as moderator of the “Imetelchat” web site and invite you to familiarize yourself with this site if you haven’t already. Congratulations on your new position at Geron. I wonder if I could trouble you to clarify the why Dr. Feller is no longer pictured on the leadership page of Geron. To my knowledge there has been no announcement as to any change in her status with the company. Thanks for your consideration. Sincerely,

No 8K as required by law and if situation does not require an 8K no clarification for interested shareholders. Here we go again. No respect for shareholders.

[Ryan]

As respectfully as possible to them … WTF

[Hoosier Investor]

Geron's recently completed IMpactMF clinical trial record still lists Faye as the Study Director. If she were no longer with the company, they would've likely updated that aspect of the record (as well).

https://clinicaltrials.gov/study/NCT045 ... not&rank=5

[biopearl123]

HI, since she supervised years of study and it concluded (or at least stopped recruiting) about the time of the disappearance of your pic and bio, I doubt the clinical trials site would change the study director. On another note this showed up in my email today:

https://s201.q4cdn.com/710325604/files/ ... Slides.pdf

An August presentation. Maybe IR doing some catch up.

[huntingonthebluffs]

Is there such a thing as co-CMOs? Since so many of us have emailed Investor Relations and probably other parts of Geron (e.g. Human Relations) as well, to no avail, there is plenty of mystery to go around. Can’t wait for the explanation and it will happen in some form. Just hope when explanation arrives, Dr. Faye Feller is still prominently in the Geron power kluge. However each passing day is more indicative that she has likely moved on, maybe we should as well.

[biopearl123]

Hunt, HI, Ryan, RC, MisterG, Is it possible they are not talking because they can’t?

[Ryan]

True that. In case others haven’t noticed, there has been a resurgence of biopharma buyouts in the past couple months. I had AI do the overview. I have to say, I highly doubt it for Geron, best Dana Carvey, “at this juncture.”
LinkedIn profile still the same, really hoping for the best here.

‘The four largest biopharma buyouts in the past few months are: Johnson & Johnson acquiring Intra-Cellular Therapies ($14.6B), Novartis acquiring Avidity Biosciences ($12B), Merck acquiring Verona Pharma ($10B), and Pfizer acquiring Metsera ($7.3B, plus contingent value rights). These deals, announced between June and October 2025, are the most significant biopharma acquisitions by value during that period. ‘

[biopearl123]

I can't imagine Geron would risk a regulatory slap on the wrist for not issuing an appropriate 8K especially after all the legal wrangling we have been through so there must be another explanation. Maybe some clarity on Wednesday.